Pulmonary Embolism: Latest Guidelines (2026)

Most current guidance: The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults was published in Circulation (March 2026) and JACC (April 2026). This is a de novo guideline — the most comprehensive and current available. PMID 41712677 | PMID 41712898

1. Risk Stratification

• Intermediate-low: PESI class ≥III or sPESI ≥1, plus RV dysfunction OR elevated troponin (not both)
• Intermediate-high: both RV dysfunction on imaging AND elevated troponin

2. Diagnosis

Pre-test Probability (PTP)

• Score ≤4 = low/moderate PTP → D-dimer testing
• Score >4 = high PTP → proceed directly to CT pulmonary angiography (CTPA)

PERC Rule

• Age <50
• Pulse <100
• SaO₂ >94%
• No unilateral leg swelling
• No hemoptysis
• No recent trauma or surgery
• No prior PE/DVT
• No hormone use

D-Dimer

• 95–98% sensitive, 40–55% specific
• Excludes PE in non-high PTP when negative (NPV 99–100%)
• Age-adjusted threshold: D-dimer < (age × 10 µg/L) in patients >50 years — shown to safely increase specificity and reduce unnecessary imaging without increasing missed PE rates
• YEARS algorithm: Can use higher D-dimer threshold (1000 ng/mL) when no YEARS criteria present

Imaging

• CTPA: Gold standard — first-line imaging for suspected PE
• V/Q scan: Alternative when CTPA contraindicated (renal failure, contrast allergy, pregnancy)
• Echocardiography: Confirms RV dysfunction; useful in high-risk unstable patients when CTPA is not immediately available
• Lower extremity US: Can support diagnosis by showing DVT

3. Treatment by Risk Category

Low-Risk PE

• Initiate anticoagulation — DOACs preferred (apixaban or rivaroxaban as first-line; dabigatran and edoxaban are alternatives after initial parenteral therapy)
• Early discharge / outpatient management — validated using either:
  • PESI / sPESI score, or
  • Hestia criteria (negative = safe for home)
• Avoid systemic thrombolysis

Intermediate-Risk PE (Submassive)

• Anticoagulate immediately (DOAC or LMWH → VKA)
• Close monitoring in monitored setting; ICU or step-down unit for intermediate-high
• Systemic thrombolysis not routine — reserve for clinical deterioration
• Catheter-directed therapy (CDT): Reasonable option for intermediate-high risk patients at centres with expertise; 2025 ESVM guidelines confirm CDT (catheter-directed thrombolysis or mechanical thrombectomy) is gaining ground here [PMID 40587333]
• PERT (PE Response Team): Multi-disciplinary team approach recommended for intermediate-high and high-risk PE

High-Risk PE (Massive)

• Systemic thrombolysis is the treatment of choice in the absence of contraindications
  • Alteplase 100 mg IV over 2 hours (standard dose)
  • 0.6 mg/kg (max 50 mg) over 15 min if cardiac arrest imminent
• Absolute contraindications to thrombolysis: Prior intracranial hemorrhage, known structural intracranial lesion, ischemic stroke within 3 months, active bleeding
• If thrombolysis contraindicated or fails: surgical embolectomy or catheter-based mechanical thrombectomy
• Anticoagulation: Unfractionated heparin (UFH) weight-based bolus + infusion preferred acutely (easily reversible)
• Vasopressor support (norepinephrine preferred for hemodynamic instability)
• Avoid aggressive fluid resuscitation (can worsen RV dilation)

4. Anticoagulation Summary

5. Duration of Anticoagulation

6. Special Populations

• Pregnancy: V/Q scan preferred over CTPA (less maternal breast radiation); LMWH is the anticoagulant of choice; peripartum management requires haematology/obstetrics co-management
• Renal impairment: UFH or VKA preferred when CrCl <15–30 mL/min; DOAC dose adjustments required
• Elderly: Age-adjusted D-dimer threshold; higher bleeding risk with anticoagulation must be weighed

7. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

• Screen all symptomatic PE patients at follow-up (3–6 months) with echocardiography
• Confirmed by right heart catheterization + V/Q scan
• Treatment:
  • Pulmonary endarterectomy (PEA): Curative in operable patients — gold standard
  • Balloon pulmonary angioplasty (BPA): For inoperable/persistent CTEPH; growing evidence base (2026 BPA-CTEPH Alliance statement [PMID 42055655])
  • Riociguat (soluble guanylate cyclase stimulator): Approved pharmacotherapy for CTEPH

Key 2026 Guideline Highlights vs. Prior Guidance

• 2026 AHA/ACC PE Guideline — Circulation (PMID 41712677) — the definitive current guideline
• 2025 ESVM Interventional VTE Guidelines (PMID 40587333) — catheter-based therapies
• 2026 BPA-CTEPH Alliance Statement (PMID 42055655) — balloon pulmonary angioplasty
• Rosen's Emergency Medicine, 9th ed. — Chapter 74

PE Risk Stratification

Step 1 — Hemodynamic Screen (First Branch Point)

• SBP <90 mmHg sustained for ≥15 minutes (not due to arrhythmia or hypovolemia)
• SBP drop >40 mmHg from baseline
• Vasopressor requirement
• Cardiac arrest (pulseless electrical activity is the most common rhythm in PE arrest)
• Severe bradycardia <40 bpm with shock features

If YES → High-Risk PE → emergency reperfusion (systemic thrombolysis or embolectomy) without delay If NO → proceed to Step 2

Step 2 — Clinical Severity Score (PESI / sPESI)

Full PESI Score

Simplified PESI (sPESI)

• sPESI = 0 → Low risk (30-day mortality ~1%)
• sPESI ≥1 → Elevated/Intermediate risk

sPESI ≥1 or PESI Class ≥III = Intermediate-risk → proceed to Step 3 for sub-classification

Step 3 — Intermediate-Risk Sub-Classification

• Echo: RV dilation, hypokinesis, or interventricular septal bowing toward LV
• CT (CTPA): RV:LV ratio ≥0.9–1.0 (88% sensitive but only 39% specific; confirm with echo)

• Troponin (I or T): Elevation reflects RV myocyte injury/ischemia; high negative predictive value for adverse outcomes when normal. High-sensitivity assays improve prognostic accuracy.
• BNP / NT-proBNP: Reflects RV pressure overload and wall stretch. BNP <50 pg/mL has 97% NPV for adverse outcomes.

Troponin T Survival Data (30 days):

Important: Despite its utility, neither troponin nor echo alone should drive reperfusion decisions. Both the positive predictive value for death is low — most biomarker-elevated patients survive with anticoagulation alone. The risk of aggressive therapy must be weighed against the potential benefit.

Step 4 — Low-Risk Identification & Outpatient Eligibility

• sPESI = 0 (or PESI Class I–II), AND
• No RV dysfunction on echo/CT, AND
• Normal troponin

Outpatient Treatment — Hestia Criteria

Summary: Full Risk Matrix

CONFIRMED ACUTE PE
        │
        ├─► Shock / Hypotension?  ──YES──► HIGH-RISK (≥15–50% mortality)
        │                                   → Systemic thrombolysis / embolectomy
        │
        └─► Stable → PESI / sPESI
                        │
                        ├─► PESI I-II / sPESI 0 → LOW-RISK (<1–3%)
                        │                          → DOAC; consider outpatient
                        │
                        └─► PESI ≥III / sPESI ≥1 → INTERMEDIATE RISK
                                        │
                                        ├─► RV dysfunction AND ↑troponin
                                        │     → INTERMEDIATE-HIGH (5–15%)
                                        │     → ICU; PERT; consider CDT
                                        │
                                        └─► RV dysfunction OR ↑troponin (not both)
                                              → INTERMEDIATE-LOW (~3–5%)
                                              → Monitored bed; anticoagulate

Additional Scoring: Bova Score

• Stage I (0–2): 1.7% PE-related mortality
• Stage II (3–4): 5.0%
• Stage III (≥5): 15.5%

ECG Findings Correlating with Higher Risk

• S1Q3T3 pattern (classic RV strain)
• Right bundle branch block (complete > incomplete, progressive RBBB is ominous)
• Inverted T waves in V1–V4, inferior leads, or right-sided leads
• ST elevation in aVR
• Prolonged QT interval
• Sinus tachycardia or new atrial fibrillation
• Widespread T-wave inversions